^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    GCR antagonist

    Related drugs:
    3d
    Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Corcept Therapeutics
    New P2 trial
    |
    CA 19-9 (Cancer antigen 19-9)
    |
    gemcitabine • albumin-bound paclitaxel • relacorilant (CORT125134)
    1m
    BELLA: Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers (clinicaltrials.gov)
    P2, N=270, Recruiting, Corcept Therapeutics | N=90 --> 270
    Enrollment change
    |
    Avastin (bevacizumab) • albumin-bound paclitaxel • relacorilant (CORT125134)
    2ms
    Evaluating AVM0703 for Treatment of COVID-19 or Influenza-mediated ARDS (clinicaltrials.gov)
    P1, N=16, Not yet recruiting, AVM Biotechnology Inc | Trial completion date: Mar 2025 --> Mar 2032 | Trial primary completion date: Dec 2024 --> Dec 2031
    Trial completion date • Trial primary completion date
    |
    dexamethasone sodium phosphate (AVM0703)
    2ms
    The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies (clinicaltrials.gov)
    P1/2, N=144, Recruiting, AVM Biotechnology Inc | Trial completion date: Jun 2025 --> Dec 2026 | Trial primary completion date: Apr 2025 --> Apr 2026
    Trial completion date • Trial primary completion date
    |
    TP53 mutation • TP53 mutation + Chr del(17p)
    |
    dexamethasone sodium phosphate (AVM0703)
    5ms
    Impact of Itraconazole on the Pharmacokinetics and Safety of Dazucorilant in Healthy, Adult Participants (clinicaltrials.gov)
    P1, N=21, Completed, Corcept Therapeutics | Active, not recruiting --> Completed | Trial completion date: Apr 2025 --> Aug 2024
    Trial completion • Trial completion date
    |
    itraconazole
    7ms
    The Selective Glucocorticoid Receptor Modulator Cort125329 Decreases Neuroinflammation and Gliosis and Enhances Myelination in the Wobbler Model of Amyotrophic Lateral Sclerosis. (PubMed, Mol Neurobiol)
    The beneficial effects of CORT125329 correlated with enhanced motor behavioral performance and trophic changes of the forelimbs. In conclusion, our results support further preclinical and clinical studies on GR modulators in sporadic amyotrophic lateral sclerosis.
    Journal • IO biomarker
    |
    TNFA (Tumor Necrosis Factor-Alpha) • HMGB1 (High Mobility Group Box 1) • TLR4 (Toll Like Receptor 4) • BDNF (Brain Derived Neurotrophic Factor)
    7ms
    Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov)
    P2, N=178, Completed, Corcept Therapeutics | Active, not recruiting --> Completed
    Trial completion • Platinum resistant
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    |
    albumin-bound paclitaxel • relacorilant (CORT125134)
    7ms
    Relacorilant in Combination With Nab-paclitaxel and Bevacizumab in Advanced, Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (clinicaltrials.gov)
    P2, N=90, Recruiting, Corcept Therapeutics | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Avastin (bevacizumab) • albumin-bound paclitaxel • relacorilant (CORT125134)
    8ms
    Effects of Hepatic Impairment on the Pharmacokinetics of Dazucorilant (clinicaltrials.gov)
    P1, N=19, Completed, Corcept Therapeutics
    New P1 trial
    8ms
    Relacorilant in Combination With Nab-paclitaxel and Bevacizumab in Advanced, Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (clinicaltrials.gov)
    P2, N=90, Not yet recruiting, Corcept Therapeutics
    New P2 trial
    |
    Avastin (bevacizumab) • albumin-bound paclitaxel • relacorilant (CORT125134)
    8ms
    PT150 Drug for Use in Alcohol Use Disorder (clinicaltrials.gov)
    P1, N=34, Recruiting, Pop Test Oncology LLC | Not yet recruiting --> Recruiting
    Enrollment open
    |
    PT150
    9ms
    Impact of Itraconazole on the Pharmacokinetics and Safety of Dazucorilant in Healthy, Adult Participants (clinicaltrials.gov)
    P1, N=21, Active, not recruiting, Corcept Therapeutics | Recruiting --> Active, not recruiting | Trial completion date: Jul 2024 --> Apr 2025
    Enrollment closed • Trial completion date
    |
    itraconazole